Effects of quercetin supplement on liver fatty deposition in patients with NAFLD: a randomized, double-blind, placebo-controlled, cross-over trial

Phase 1

Conditions: nonalcoholic fatty liver disease (NAFLD)

Registration Number: ITMCTR2100004988

Lead Sponsor: Second Affiliated Hospital of Army Medical University, PLA

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: Not specified

Inclusion Criteria

1. Resident aged 18-65 years in Chongqing;
2. No history of drinking or drinking alcohol equivalent to less than 210g/week (women <140g/week);
3. Excluding specific diseases that can lead to fatty liver, such as viral hepatitis, drug-induced hepatitis, total parenteral nutrition, hepatolenticular degeneration, and autoimmune liver disease;
4. Liver imaging manifestations (B-ultrasound or MRI-PDFF quantitative intrahepatic fat content>5.56%) meet the diagnostic criteria of diffuse fatty liver and no other reasons can be explained.

Exclusion Criteria

1. Histological changes of liver biopsy within the past 6 months meet the pathological diagnostic criteria of significant or progressive fibrosis NASH or liver cirrhosis;
2. Taking lipid-lowering drugs (such as statins, fibrates, etc.) and drugs or health products that may affect liver fat content within the past 3 months (such as silibinin, ursodeoxycholic acid, bicyclol, phosphatidylcholine and vitamin E, glucocorticoids, fish oil, etc.);
3. Those with diabetes who have been treated with insulin or who have undergone bariatric surgery for obesity;
4. Patients with severe cardiac insufficiency, liver and kidney insufficiency, malignant tumor, pregnancy and lactation, or women and men who wish to become pregnant or have children during the study;
5. Patients with a history of mental illness who cannot cooperate with the research of this project;
6. There are contraindications to MRI;
7. Possible circumstances that other researchers believe would prevent completion of the study.